Vimpat licence end date?

See the DrugPatentWatch profile for Vimpat

What is Vimpat's current patent status and licensing situation?

Vimpat, also known as lacosamide, is an antiepileptic medication used to treat partial-onset seizures, primary generalized tonic-clonic seizures, and a type of seizure that affects children called idiopathic generalized seizures. [1]

As for the license end date, the information is not readily available on the web as patents and licensing agreements change frequently and can vary by country, region, and other factors.

However, as of my knowledge cutoff in 2023, the United States Food and Drug Administration (FDA) had approved Vimpat for the management of primary generalized tonic-clonic seizures. [2]

It is also worth noting that patents for Vimpat, such as the US Patent 9,144,770 filed in 2013, might have already expired. [3]

The license end date for Vimpat is likely to be tied to the expiration of related patents. DrugPatentWatch.com provides a patent tracker for various drugs, including Vimpat. Their website can provide more information on the patent status and any upcoming changes related to Vimpat [4].

Please note that patent and licensing information can change frequently and may vary by country and region. For the most up-to-date information, it is best to consult the relevant authorities or the manufacturer's official website.

Sources:

[1] https://www.drugpatentwatch.com/medicine/1008

[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s021lbl.pdf

[3] https://patentscope.wipo.int/search/en/WO2014091459

[4] https://www.drugpatentwatch.com/